Publicaciones en las que colabora con MARÍA DOLORES CABALLERO BARRIGÓN (16)

2019

  1. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1703-1712

2017

  1. Plitidepsin: Design, development, and potential place in therapy

    Drug Design, Development and Therapy, Vol. 11, pp. 253-264

2014

  1. Late differentiation syndrome in acute promyelocytic leukemia: A challenging diagnosis

    Hematology Reports, Vol. 6, Núm. 4, pp. 75-77

2008

  1. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: A prospective study from the GEL-TAMO study group

    European Journal of Haematology, Vol. 80, Núm. 3, pp. 227-235

2006

  1. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol

    Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 2, pp. 172-183

2005

  1. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)

    Clinical Cancer Research, Vol. 11, Núm. 21, pp. 7757-7763

  2. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning

    Biology of Blood and Marrow Transplantation, Vol. 11, Núm. 6, pp. 437-447

2004

  1. Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation

    Bone Marrow Transplantation, Vol. 33, Núm. 2, pp. 183-187

  2. Graft vs. host disease and graft vs. myeloma effect after non-myeloablative allogeneic transplantation

    Leukemia and Lymphoma, Vol. 45, Núm. 9, pp. 1725-1729

  3. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: A single-centre sequential-cohort study

    Bone Marrow Transplantation, Vol. 34, Núm. 8, pp. 675-682

2003

  1. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning

    Bone Marrow Transplantation, Vol. 31, Núm. 5, pp. 387-392

  2. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation

    Experimental Hematology

2002

  1. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation

    Leukemia, Vol. 16, Núm. 8, pp. 1423-1431

  2. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx®), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: Results from a prospective phase II study

    Haematologica, Vol. 87, Núm. 8, pp. 822-827

1999

  1. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation

    Bone Marrow Transplantation, Vol. 24, Núm. 12, pp. 1279-1283

  2. Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation

    Bone Marrow Transplantation, Vol. 23, Núm. 9, pp. 901-905